192 related articles for article (PubMed ID: 11708181)
1. Efavirenz (Sustiva).
Res Initiat Treat Action; 2000 Mar; 6(1):22-3. PubMed ID: 11708181
[No Abstract] [Full Text] [Related]
2. Options when HIV treatments fail.
Treat Rev; 1998; (No 28):7-9. PubMed ID: 11365426
[TBL] [Abstract][Full Text] [Related]
3. Switching from protease inhibitors to the non-nuke efavirenz.
TreatmentUpdate; 2001; 12(12):3. PubMed ID: 11570089
[No Abstract] [Full Text] [Related]
4. New expanded access drugs for use in combination therapy.
Notes Undergr; 1998; (No 37):suppl 1-2. PubMed ID: 11365823
[TBL] [Abstract][Full Text] [Related]
5. Efavirenz and Fortovase.
Baker R
BETA; 1998 Jul; ():9. PubMed ID: 11365572
[TBL] [Abstract][Full Text] [Related]
6. Don't mix Sustiva with Fortovase.
Posit Aware; 1998; 9(5):17. PubMed ID: 11365885
[TBL] [Abstract][Full Text] [Related]
7. Didanosine (Videx).
Res Initiat Treat Action; 2000 Mar; 6(1):8-9. PubMed ID: 11708189
[No Abstract] [Full Text] [Related]
8. Zidovudine (Retrovir).
Res Initiat Treat Action; 2000 Mar; 6(1):6-7. PubMed ID: 11708188
[No Abstract] [Full Text] [Related]
9. Delavirdine (Rescriptor).
Res Initiat Treat Action; 2000 Mar; 6(1):20-1. PubMed ID: 11708180
[No Abstract] [Full Text] [Related]
10. Nevirapine (Viramune).
Res Initiat Treat Action; 2000 Mar; 6(1):18-9. PubMed ID: 11708179
[No Abstract] [Full Text] [Related]
11. Abacavir (Ziagen).
Res Initiat Treat Action; 2000 Mar; 6(1):16-7. PubMed ID: 11708178
[No Abstract] [Full Text] [Related]
12. Lamivudine (Epivir).
Res Initiat Treat Action; 2000 Mar; 6(1):14-5. PubMed ID: 11708177
[No Abstract] [Full Text] [Related]
13. Stavudine (Zerit).
Res Initiat Treat Action; 2000 Mar; 6(1):12-3. PubMed ID: 11708176
[No Abstract] [Full Text] [Related]
14. Zalcitabine (Hivid).
Res Initiat Treat Action; 2000 Mar; 6(1):10-1. PubMed ID: 11708175
[No Abstract] [Full Text] [Related]
15. Efavirenz (Sustiva) on fast-track for FDA accelerated approval. Food and Drug Administration.
Baker R
BETA; 1998 Jul; ():9. PubMed ID: 11365571
[TBL] [Abstract][Full Text] [Related]
16. Sustiva: revised drug-interaction information.
AIDS Treat News; 2006; (421):5. PubMed ID: 17407831
[TBL] [Abstract][Full Text] [Related]
17. Performance of a quadruple combination including nelfinavir plus efavirenz in naive subjects with high baseline viral load and in patients failing protease inhibitor-containing regimens.
Barreiro P; Oller V; Soriano V; Nuñez M; Rodríguez-Rosado R; González-Lahoz J
J Acquir Immune Defic Syndr; 2001 Apr; 26(4):391-2. PubMed ID: 11317086
[No Abstract] [Full Text] [Related]
18. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy.
Bacheler L; Jeffrey S; Hanna G; D'Aquila R; Wallace L; Logue K; Cordova B; Hertogs K; Larder B; Buckery R; Baker D; Gallagher K; Scarnati H; Tritch R; Rizzo C
J Virol; 2001 Jun; 75(11):4999-5008. PubMed ID: 11333879
[TBL] [Abstract][Full Text] [Related]
19. In vitro anti-HIV-1 synergy between non-nucleoside reverse transcriptase inhibitors nevirapine and efavirenz.
Kollmann C; Tremblay C; Giguel F; Chou TC; Hirsch MS
Antivir Ther; 2001 Jun; 6(2):143-4. PubMed ID: 11491419
[No Abstract] [Full Text] [Related]
20. Efavirenz expanded access broadened.
Highleyman L
BETA; 1998 Apr; ():3. PubMed ID: 11365262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
